Abstracts tagged "adult-onset Still’s disease and canakinumab"

Abstract Number: 365 • 2017 ACR/ARHP Annual Meeting
Canakinumab Treatment in Patients with Still’s Disease: A Pooled Analysis of Systemic Juvenile Idiopathic Arthritis Data By Age Groups
Eugen Feist¹, Pierre Quartier², Bruno Fautrel³, Rayfel Schneider⁴, Paolo Sfriso⁵, Petros Efthimiou⁶, Luca Cantarini⁷, Karine Lheritier⁸, Karolynn Leon⁹ and Antonio Speziale⁸, ¹Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin, Berlin, Germany, ²Necker-Enfants Malades Hospital, Paris, France, ³UPMC University Paris 06, Pitié-Salpétrière Hospital, Paris, France, ⁴University of Toronto and The Hospital for Sick Children, Toronto, ON, Canada, ⁵University of Padova, Padova, Italy, ⁶Medicine/Rheumatology, New York University School of Medicine/NYU Langone Health, New York, NY, ⁷University of Siena, Siena, Italy, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Still’s disease presents in pediatric and adult patients as a disease continuum with similar symptoms and pathophysiology.1,2 The objective of this analysis was to…
Abstract Number: 1246 • 2015 ACR/ARHP Annual Meeting
Gene Expression Analysis of Adult Onset Still’s Disease and Systemic Juvenile Idiopathic Arthritis Suggest a Single Disease Continuum
N. Nirmala¹, Arndt Brachat², Eugen Feist³, Norbert Blank⁴, Christof Specker⁵, Matthias Witt⁶, Jan Zernicke⁷, Alberto Martini⁸ and Guido Junge⁹, ¹Novartis Institutes for Biomedical Research, Cambridge, MI, ²Novartis Institutes for Biomedical Research, Basel, Switzerland, ³Rheumatology and Clinical Immunology, Charite University Hospital, Berlin, Germany, ⁴University of Heidelberg, Heidelberg, Germany, ⁵Kliniken Essen Süd, Essen, Germany, ⁶Division for Rheumatology, University of Munich, Munich, Germany, ⁷Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ⁸Department of Pediatrics, G Gaslini Institute, Genova, Italy, ⁹Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Adult-onset Still's disease (AOSD) is a rare auto-inflammatory disorder.1 The superimposable systemic clinical features of AOSD and the pediatric syndrome known as systemic juvenile…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].